CA2263911A1 - Treatment of autoimmune diseases - Google Patents
Treatment of autoimmune diseasesInfo
- Publication number
- CA2263911A1 CA2263911A1 CA002263911A CA2263911A CA2263911A1 CA 2263911 A1 CA2263911 A1 CA 2263911A1 CA 002263911 A CA002263911 A CA 002263911A CA 2263911 A CA2263911 A CA 2263911A CA 2263911 A1 CA2263911 A1 CA 2263911A1
- Authority
- CA
- Canada
- Prior art keywords
- autoimmune diseases
- blood
- aliquot
- treatment
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/32—Oxygenators without membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0216—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Abstract
An autoimmune vaccine is provided for administration to human patients to alleviate the symptoms of autoimmune diseases such as rheumatoid arthritis. The vaccine comprises an aliquot of the patient's blood, containing, inter alia , leukocytes having upregulated expression of various cell surface markers and lymphocytes containing decreased amounts of certain stress proteins. It is produced by subjecting the blood aliquot extracorporeally to certain stressors, namely oxidizing agents, UV radiation and elevated temperature.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9617611.0 | 1996-08-22 | ||
GBGB9617611.0A GB9617611D0 (en) | 1996-08-22 | 1996-08-22 | Treatment of autoimmune disease |
US08/754,348 | 1996-11-22 | ||
US08/754,348 US5980954A (en) | 1992-02-07 | 1996-11-22 | Treatment of autoimmune diseases |
PCT/CA1997/000564 WO1998007436A1 (en) | 1996-08-22 | 1997-08-11 | Treatment of autoimmune diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2263911A1 true CA2263911A1 (en) | 1998-02-26 |
CA2263911C CA2263911C (en) | 2007-01-16 |
Family
ID=26309905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002263911A Expired - Fee Related CA2263911C (en) | 1996-08-22 | 1997-08-11 | Treatment of autoimmune diseases |
Country Status (12)
Country | Link |
---|---|
US (2) | US5980954A (en) |
EP (1) | EP0920322B9 (en) |
JP (1) | JP3883013B2 (en) |
AT (1) | ATE237339T1 (en) |
AU (1) | AU724265B2 (en) |
CA (1) | CA2263911C (en) |
DE (1) | DE69721006T2 (en) |
DK (1) | DK0920322T3 (en) |
ES (1) | ES2199367T3 (en) |
NZ (1) | NZ334635A (en) |
PT (1) | PT920322E (en) |
WO (1) | WO1998007436A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980954A (en) | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6669965B2 (en) * | 1992-02-07 | 2003-12-30 | Vasogen Ireland Limited | Method of treating atherosclerosis |
GB9617611D0 (en) * | 1996-08-22 | 1996-10-02 | Vasogen Inc | Treatment of autoimmune disease |
US6066489A (en) | 1996-08-30 | 2000-05-23 | Arrow International, Inc. | Method for treating blood borne viral pathogens such as immunodeficiency virus |
CA2206180A1 (en) * | 1997-05-27 | 1998-11-27 | Vasogen Inc. | Treatment of chronic post-traumatic pain syndromes |
ES2210814T3 (en) * | 1997-09-12 | 2004-07-01 | Vasogen Ireland Limited | STRESS TREATMENT AND PRIOR CONDITIONING AGAINST STRESS. |
CA2244554A1 (en) * | 1998-07-30 | 2000-01-30 | Vasogen Inc. | Inhibition of graft versus host disease |
US6264646B1 (en) | 1998-11-13 | 2001-07-24 | Vasogen Ireland Limited | Method for preventing and reversing atherosclerosis in mammals |
ATE233093T1 (en) * | 1998-11-13 | 2003-03-15 | Vasogen Ireland Ltd | MEDICINAL PRODUCTS FOR PREVENTING AND REVERSING ATHEROSCLERosis IN MAMMALS |
EP1146885B1 (en) * | 1999-01-12 | 2003-05-28 | Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal | Pre-conditioning against cell death |
CA2269364A1 (en) * | 1999-04-19 | 2000-10-19 | Vasogen Ireland Limited | Treatment of inflammatory and allergic disorders |
CA2271190A1 (en) * | 1999-05-06 | 2000-11-06 | Vasogen Ireland Limited | Improved method for treating mammals with modified mammalian blood |
WO2001019318A1 (en) | 1999-09-16 | 2001-03-22 | Vasogen Ireland Limited | Apparatus and process for conditioning mammalian blood |
JP2003510284A (en) * | 1999-09-24 | 2003-03-18 | バソジェン アイルランド リミテッド | Combination therapy for the treatment of atherosclerosis |
CA2296997A1 (en) * | 2000-01-18 | 2001-07-18 | Vasogen Ireland Limited | Treatment of congestive heart failure |
CA2297448A1 (en) * | 2000-01-28 | 2001-07-28 | Vasogen Inc. | Improved inhibition of graft versus host disease |
US6800300B1 (en) | 2000-03-31 | 2004-10-05 | Vasogen Ireland Limited | Method for treating autoimmune and alloimmune diseases |
AU2001251612A1 (en) * | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
US6970740B2 (en) * | 2000-04-19 | 2005-11-29 | Clemson University | UVC rediation therapy for leukemia |
WO2001080939A2 (en) * | 2000-04-19 | 2001-11-01 | Clemson University | Uvc radiation therapy for chronic lymphocytic leukemia |
CA2308105A1 (en) * | 2000-05-11 | 2001-11-11 | Vasogen Ireland Limited | Treatment of il-10 deficiencies |
CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
CA2309518A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
CA2309417A1 (en) * | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
CA2324199A1 (en) * | 2000-10-25 | 2002-04-25 | Vasogen Ireland Limited | Chronic lymphocytic leukemia treatment |
CA2327631A1 (en) * | 2000-12-05 | 2002-06-05 | Vasogen Ireland Limited | Inflammatory cytokine secretion inhibition |
CA2327630A1 (en) * | 2000-12-05 | 2002-06-05 | Vasogen Ireland Limited | Transforming growth factor regulation |
US20020090360A1 (en) * | 2000-12-05 | 2002-07-11 | Bolton Anthony E. | Inflammatory cytokine secretion inhibition |
CA2333494A1 (en) * | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
US7122208B2 (en) | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
CN1310652C (en) * | 2001-11-29 | 2007-04-18 | 特拉科斯有限公司 | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells |
KR20040108707A (en) * | 2002-04-10 | 2004-12-24 | 바소겐 아일랜드 리미티드 | Electrocardiographic aspects of chf treatment |
JP3927922B2 (en) * | 2003-05-21 | 2007-06-13 | Ykk株式会社 | Slide body for slide fastener and slider equipped with the spring body |
US7368542B2 (en) | 2003-06-09 | 2008-05-06 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
US7892751B2 (en) * | 2003-06-09 | 2011-02-22 | Redox-Reactive Reagents Llc | Method of detecting or diagnosing of a neurodegenerative disease or condition |
US9557325B2 (en) * | 2003-06-09 | 2017-01-31 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of proteins by oxidation-reduction reactions |
WO2005018715A1 (en) * | 2003-07-31 | 2005-03-03 | Lipidviro Tech | Ozone delivery system including gas-fluid contacting devices and methods of use |
US20050189302A1 (en) * | 2003-07-31 | 2005-09-01 | Latino Joseph S. | Viral inactivation using ozone |
US7736494B2 (en) * | 2003-07-31 | 2010-06-15 | Acquisci, Inc. | Ozone delivery system including a variable pitch gas-fluid contact device |
US20100316730A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of cardiovascular diseases with ozone |
US20100318014A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of acute ischemic brain stroke with ozone |
US20100316727A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of inflammatory disorders with ozone |
ES2694252T3 (en) * | 2004-04-02 | 2018-12-19 | Swedish Orphan Biovitrum Ab (Publ) | Methods to reduce the aggregation of IL-1ra |
WO2006115509A2 (en) * | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
EP1773360A4 (en) * | 2004-07-20 | 2009-09-02 | Vasogen Ireland Ltd | Acute inflammatory condition treatment |
US20060210644A1 (en) * | 2004-12-16 | 2006-09-21 | Bruce Levin | Materials, methods, and devices for treatment of arthropathies and spondylopathies |
US20090232834A1 (en) * | 2005-07-18 | 2009-09-17 | Al-Harbi Saleh A | Methods and Agents to Treat Autoimmune Diseases |
WO2008124096A1 (en) * | 2007-04-04 | 2008-10-16 | Gaia Medical Institute | Systems and methods for analyzing persistent homeostatic perturbations |
US9358292B2 (en) | 2007-04-08 | 2016-06-07 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders |
US20090104212A1 (en) * | 2007-08-06 | 2009-04-23 | Immunolight | Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption |
KR101322247B1 (en) * | 2007-09-06 | 2013-10-25 | 삼성전자주식회사 | suction brush for use in vacuum cleaner and height adjusting method thereof |
US9439897B2 (en) | 2007-11-06 | 2016-09-13 | Immunolight, Llc | Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders |
TWI458512B (en) * | 2008-02-21 | 2014-11-01 | Immunolight Llc | Compositions for treating cell proliferation disorders and systems for producing auto-vaccines using plasmonics enhanced photospectral therapy (pepst) and exciton-plasmon enhanced phototherapy (epep) |
CN113274496A (en) * | 2008-04-04 | 2021-08-20 | 免疫之光有限责任公司 | Non-invasive system and method for in situ photobiomodulation |
EP2729175B1 (en) | 2011-07-08 | 2021-12-01 | Duke University | System for light stimulation within a medium |
ITMI20131667A1 (en) * | 2013-10-09 | 2015-04-10 | Ind Paolo Gobbi Frattini | METHOD TO PRE-TREAT THE HEMATIC CELLS BEFORE SEPARATION. |
EP3157519B1 (en) | 2014-06-19 | 2021-05-12 | Immunolight, LLC | Methods and systems for treating cell proliferation disorders with psoralen derivatives |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1068428C2 (en) | 1957-05-21 | 1960-04-21 | Hermann Dr Med Jentjens | Process and device for the production of oxygenated blood |
US3715430A (en) * | 1969-08-04 | 1973-02-06 | E Ryan | Purified oxygen gas containing ozone and higher oxygen polymers |
US3925344A (en) | 1973-04-11 | 1975-12-09 | Community Blood Council | Plasma protein substitute |
US4061736A (en) | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4473496A (en) | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
JPS58198466A (en) | 1982-05-12 | 1983-11-18 | Teijin Ltd | 5-thiaprostaglandins and their preparations |
FR2528848A1 (en) | 1982-06-16 | 1983-12-23 | Sanofi Sa | NEW THIENO-PYRIDONE DERIVATIVE, PREPARATION METHOD AND THERAPEUTIC APPLICATION |
US4613322A (en) * | 1982-12-08 | 1986-09-23 | Edelson Richard Leslie | Method and system for externally treating the blood |
US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
US4695647A (en) | 1984-03-22 | 1987-09-22 | Drug Science Foundation | Aromatic derivatives of 13-azaprostanoic acid |
US4659726A (en) | 1984-04-19 | 1987-04-21 | Kanebo, Ltd. | Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same |
US4600531A (en) | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
DD249143A3 (en) * | 1985-03-20 | 1987-09-02 | Ilmenau Tech Hochschule | DEVICE FOR THE PHYSIOLOGICAL THERAPEUTICALLY ACTIVE OPTICAL IRRADIATION OF OVERLAPPED VENEER BLOOD |
US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
US4632980A (en) * | 1985-04-03 | 1986-12-30 | Immunologics | Ozone decontamination of blood and blood products |
US5194590A (en) | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US4826811A (en) | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
DE8704467U1 (en) * | 1987-01-15 | 1988-05-26 | Quarzlampenfabrik Dr.-Ing. Felix W. Mueller Gmbh & Co Kg, 4300 Essen, De | |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
GB8711614D0 (en) | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
DE68921912D1 (en) * | 1988-04-29 | 1995-05-04 | Medizone Int Inc | Device for the controlled generation and administration of ozone. |
US4983637A (en) | 1988-06-24 | 1991-01-08 | Stephen Herman | Method for treating viral infection of HIV |
WO1992010198A1 (en) * | 1990-12-06 | 1992-06-25 | Johnson & Johnson Research Pty Limited | Immunotherapeutic agents, compositions and methods |
US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
WO1993015778A1 (en) | 1992-02-07 | 1993-08-19 | Anthony Ernest Bolton | Method of inhibiting the aggregation of blood platelets |
US5980954A (en) | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
ATE350046T1 (en) | 1992-02-07 | 2007-01-15 | Vasogen Ireland Ltd | USE OF BLOOD WITH INCREASED NITROGEN OXIDE CONCENTRATION TO PRODUCE A MEDICATION |
US5591457A (en) | 1992-02-07 | 1997-01-07 | Vasogen Inc | Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human |
ES2205026T3 (en) | 1995-05-05 | 2004-05-01 | Vasogen Ireland Limited | EFFECTS OF ENDOTELIAL COATING AND TREATMENT OF VASOSPASMIC DISORDERS. |
US6264646B1 (en) | 1998-11-13 | 2001-07-24 | Vasogen Ireland Limited | Method for preventing and reversing atherosclerosis in mammals |
-
1996
- 1996-11-22 US US08/754,348 patent/US5980954A/en not_active Expired - Fee Related
-
1997
- 1997-08-11 DE DE69721006T patent/DE69721006T2/en not_active Expired - Fee Related
- 1997-08-11 DK DK97935400T patent/DK0920322T3/en active
- 1997-08-11 CA CA002263911A patent/CA2263911C/en not_active Expired - Fee Related
- 1997-08-11 ES ES97935400T patent/ES2199367T3/en not_active Expired - Lifetime
- 1997-08-11 EP EP97935400A patent/EP0920322B9/en not_active Expired - Lifetime
- 1997-08-11 WO PCT/CA1997/000564 patent/WO1998007436A1/en active IP Right Grant
- 1997-08-11 JP JP51019398A patent/JP3883013B2/en not_active Expired - Fee Related
- 1997-08-11 PT PT97935400T patent/PT920322E/en unknown
- 1997-08-11 NZ NZ334635A patent/NZ334635A/en unknown
- 1997-08-11 AT AT97935400T patent/ATE237339T1/en not_active IP Right Cessation
- 1997-08-11 AU AU38442/97A patent/AU724265B2/en not_active Ceased
-
1999
- 1999-01-05 US US09/225,353 patent/US6569467B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU3844297A (en) | 1998-03-06 |
EP0920322B9 (en) | 2003-10-29 |
CA2263911C (en) | 2007-01-16 |
ES2199367T3 (en) | 2004-02-16 |
PT920322E (en) | 2003-11-28 |
EP0920322A1 (en) | 1999-06-09 |
AU724265B2 (en) | 2000-09-14 |
DE69721006D1 (en) | 2003-05-22 |
JP3883013B2 (en) | 2007-02-21 |
ATE237339T1 (en) | 2003-05-15 |
DE69721006T2 (en) | 2004-01-22 |
NZ334635A (en) | 2000-08-25 |
WO1998007436A1 (en) | 1998-02-26 |
JP2000517302A (en) | 2000-12-26 |
EP0920322B1 (en) | 2003-04-16 |
DK0920322T3 (en) | 2003-08-04 |
US6569467B1 (en) | 2003-05-27 |
US5980954A (en) | 1999-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2263911A1 (en) | Treatment of autoimmune diseases | |
EP0223126A3 (en) | A system for the collection, treatment and return of a patient's blood | |
Fuchs | The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis | |
AU2742892A (en) | An anticoagulant substance obtained from urine | |
IL91184A0 (en) | N-2,3-butadienyl tri-and tetraaminoalkane derivatives | |
FI913818A0 (en) | NOW TROMBOLYTISKT AEMNE. | |
HK1055080A1 (en) | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders | |
CA2194485A1 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
EP1002538A3 (en) | Stem cell and lymphocyte storage | |
AU7479596A (en) | Induction of immunological tolerance | |
GB9617611D0 (en) | Treatment of autoimmune disease | |
IT8721115A0 (en) | PHYTO-PREPARATION FOR THE TREATMENT OF SKIN DISEASES. | |
AU2459188A (en) | Anticoagulative protein pp4-x, and its preparation and use | |
EP0668771A4 (en) | Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs. | |
AU5276296A (en) | Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells | |
GR3006147T3 (en) | ||
McCarthy | Physicians' Responsibilites in the Treatment of AIDS Patients | |
AU1162788A (en) | Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases | |
IT8530823V0 (en) | THERAPEUTIC TABLE FOR THE TREATMENT OF RHEUMATISMS AND SOME ALLERGIES THROUGH THE BALSAMIC VAPOR ACTING ON THE SKIN, ON THE MUSCLES AND ON THE BODY OF THE PATIENT. | |
Mason | ‘More Volts, Igor!’Electricity beyond the grave | |
Sharada et al. | Adenosine deaminase activity in peripheral blood lymphocytes and serum of patients with alcoholic liver disease. | |
UA37041A (en) | Method for stimulation of functional activity of t-lymphocytes | |
IT8820565A0 (en) | MEDICAL HEALTH ACCESSORY FOR THE IMMEDIATE TREATMENT OF CONUSIVE STRAIN TRAUMAS OF THE GALVLE. | |
Killip | Coronary bypass surgery. Where we stand today. | |
方允中 et al. | NEW FINDINGS ABOUT THE ANTIGENANTIBODY REACTION BETWEEN ANTIBOVINE CuZn-SOD ANTISERA AND CuZnSOD IN THE BLOOD OF CANCER PATIENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |